Biomea Fusion Highlights Recent Updates and Anticipated 2024 …
WEBJan 9, 2024 — Open label portion of Phase II COVALENT-112 study readout in 40 patients with type 1 diabetes expected in 2024. REDWOOD CITY, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the ...
Investors & Media | Biomea Fusion
WEBBiomea Fusion is a clinical stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat patients with metabolic disease and genetically defined cancers.
Press Releases | Biomea Fusion
WEBBMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing. May 02, 2024.
Biomea Fusion Reports Second Quarter 2024 Financial Results and ...
WEBJul 31, 2024 — Continued the development of the Biomea FUSION™ Platform technology. SECOND QUARTER 2024 FINANCIAL RESULTS. Cash, Cash Equivalents, and Restricted Cash: As of June 30, 2024, the Company had cash, cash equivalents and restricted cash of $113.7 million, compared to $177.2 million as of December 31, 2023.
Biomea Fusion Announces 2022 Clinical Development Plan to …
WEBREDWOOD CITY, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible small molecules to treat and improve the lives of patients with genetically defined.
Biomea Fusion Announces Positive Data from Initial Cohorts of …
WEBMar 28, 2023 — Biomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes; 100 mg Cohort 3 Demonstrated an 89% Response Rate and 1% Median Reduction in HbA1c at Day 28
Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial ...
WEBMar 28, 2023 — Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights. Mar 28, 2023 at 4:02 PM EDT. PDF Version. Expanded clinical development footprint of BMF-219, the company’s lead investigational, orally administered, covalent menin inhibitor, to eight liquid and solid tumor indications and type 2 diabetes ...
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes …
WEBREDWOOD CITY, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers ...
Events - Biomea Fusion
WEBVirtual Fireside Chat with Oppenheimer & Co.: Type 2 Diabetes and New Treatment Options with Biomea Fusion (BMEA) Mgmt. & Key Opinion Leaders. Mar 2, 2023 at 12:00 PM EST.
Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical …
WEBREDWOOD CITY, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), announced that the Company has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea’s ongoing Phase I/II clinical.